Last edition
News about "Glenmark Specialty S.A."
Glenmark Secures China's Approval For RYALTRIS
Glenmark Pharmaceuticals has received regulatory approval in China for RYALTRIS. Combining olopatadine hydrochloride and mometasone furoate, it offers dual-action relief from nasal symptoms, further strengthening Glenmark’s position as a global leader in respiratory innovation.
Glenmark Specialty S.A. | 11/11/2025 | By Dineshwori | 159
Glenmark Secures USD 1.0 Billion Licensing Deal for Next-Gen Cancer Drug with Chinese Partner
Under the terms of the deal, Glenmark will make an upfront payment of USD 18 million and may pay up to USD 1.093 billion in regulatory and commercial milestone payments, in addition to royalties tied to future sales.
Glenmark Specialty S.A. | 25/09/2025 | By Darshana | 137
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy